Germline variants associated with toxicity to immune checkpoint blockade-Reference-Cited by-同舟云学术

Germline variants associated with toxicity to immune checkpoint blockade

Published:2022-12 Issue:12 Volume:28 Page:2584-2591
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Groha Stefan,Alaiwi Sarah Abou^ORCID,Xu Wenxin^ORCID,Naranbhai Vivek,Nassar Amin H.^ORCID,Bakouny Ziad^ORCID,El Zarif Talal^ORCID,Saliby Renee Maria,Wan Guihong^ORCID,Rajeh Ahmad,Adib Elio,Nuzzo Pier V.^ORCID,Schmidt Andrew L.,Labaki Chris,Ricciuti Biagio,Alessi Joao Victor,Braun David A.,Shukla Sachet A.^ORCID,Keenan Tanya E.,Van Allen Eliezer^ORCID,Awad Mark M.,Manos Michael,Rahma Osama,Zubiri Leyre,Villani Alexandra-Chloe,Fairfax Benjamin^ORCID,Hammer Christian,Khan Zia^ORCID,Reynolds Kerry,Semenov Yevgeniy^ORCID,Schrag Deborah,Kehl Kenneth L.^ORCID,Freedman Matthew L.^ORCID,Choueiri Toni K.^ORCID,Gusev Alexander^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-022-02094-6.pdf

Reference52 articles.

1. Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).

2. June, C. H., Warshauer, J. T. & Bluestone, J. A. Corrigendum: Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat. Med. 23, 1004 (2017).

3. Esfahani, K. et al. Moving towards personalized treatments of immune-related adverse events. Nat. Rev. Clin. Oncol. 17, 504–515 (2020).

4. Boutros, C. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13, 473–486 (2016).

5. Koon, H. & Atkins, M. Autoimmunity and immunotherapy for cancer. N. Engl. J. Med. 354, 758–760 (2006).

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights;Trends in Cancer;2024-08

2. Interleukin-7 Risk Allele, Lymphocyte Counts, and Autoantibodies for Prediction of Risk of Immune-Related Adverse Events in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma;Oncology;2024-07-30

3. Evaluation of the associations of interlukin‐7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: A replication study of a Japanese population, based on the findings of a European genome‐wide association study;Hepatology Research;2024-07-11

4. Restricting datasets to classifiable samples augments discovery of immune disease biomarkers;Nature Communications;2024-06-26

5. PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from All of Us cohort;2024-06-20